We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+5.79%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$64.7B
AUM Growth
+$5.24B
Cap. Flow
+$2.36B
Cap. Flow %
3.65%
Top 10 Hldgs %
20.54%
Holding
3,821
New
235
Increased
1,962
Reduced
1,317
Closed
186

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$40.1M
2
T icon
AT&T
T
+$28M
3
FTXO icon
First Trust Nasdaq Bank ETF
FTXO
+$24.3M
4
TTE icon
TotalEnergies
TTE
+$23.7M
5
WMT icon
Walmart Inc
WMT
+$22.8M

Sector Composition

Rank Sector Weight
1 Technology 10.68%
2 Financials 9.21%
3 Healthcare 8.48%
4 Industrials 6.92%
5 Consumer Discretionary 5.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DK icon
3601
CALL
Delek US
DK
$3.58B
$1K ﹤0.01%
18,300
-700
-4% -$34.5K
HAL icon
3602
CALL
Halliburton
HAL
$26.6B
$1K ﹤0.01%
16,200
-5,300
-25% -$219K
INTC icon
3603
CALL
Intel
INTC
$513B
$1K ﹤0.01%
36,700
+25,200
+219% +$1.23M
JCI icon
3604
CALL
Johnson Controls International
JCI
$92.2B
$1K ﹤0.01%
46,400
+1,300
+3% +$47.9K
OPK icon
3605
CALL
Opko Health
OPK
$1.02B
$1K ﹤0.01%
36,000
OVV icon
3606
CALL
Ovintiv
OVV
$16.4B
$1K ﹤0.01%
3,660
+240
+7% +$15.6K
OZK icon
3607
CALL
Bank OZK
OZK
$5.61B
$1K ﹤0.01%
+13,000
New +$534K
ZION icon
3608
CALL
Zions Bancorporation
ZION
$10.3B
$1K ﹤0.01%
+14,400
New +$760K
HCR
3609
CALL
DELISTED
Hi-Crush Inc. Common Stock
HCR
$1K ﹤0.01%
+22,700
New +$285K
CYHHZ
3610
DELISTED
Community Health Systems, Inc. Series A Contingent Value Rights
CYHHZ
$1K ﹤0.01%
42,718
-645
-1% -$15
AIA icon
3611
iShares Asia 50 ETF
AIA
$4.93B
-81,682
Closed -$5.13M
AKAM icon
3612
CALL
Akamai
AKAM
$15.9B
-33,500
Closed -$206K
AKBA icon
3613
Akebia Therapeutics
AKBA
$252M
-38,698
Closed -$386K
ALGT icon
3614
Allegiant Air
ALGT
$2.57B
-1,757
Closed -$244K
ALK icon
3615
CALL
Alaska Air
ALK
$5.58B
-20,700
Closed -$1K
ALT icon
3616
Altimmune
ALT
$599M
-1,486
Closed -$20K
ASUR icon
3617
Asure Software
ASUR
$250M
-28,392
Closed -$453K
AXDX
3618
DELISTED
Accelerate Diagnostics
AXDX
-1,056
Closed -$235K
AZN icon
3619
CALL
AstraZeneca
AZN
$250B
-9,250
Closed -$1K
BHE icon
3620
Benchmark Electronics
BHE
$2.96B
-36,394
Closed -$1.06M
BLD
3621
DELISTED
TopBuild
BLD
-5,243
Closed -$411K
BLE
3622
DELISTED
BlackRock Municipal Income Trust II
BLE
-11,940
Closed -$170K
BOOM icon
3623
DMC Global
BOOM
$157M
-5,112
Closed -$230K
BBBY
3624
Bed Bath & Beyond
BBBY
$442M
-8,497
Closed -$215K
CDE icon
3625
Coeur Mining
CDE
$17.9B
-13,940
Closed -$106K

Similar funds

Raymond James & Associates's Q3 2018 Portfolio in Review

As of Q3 2018, Raymond James & Associates held 3,821 positions worth $64.7B, up 8.8% from $59.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates deployed $2.36B of net new capital in Q3 2018, opening 235 new positions and adding to 1,962 existing holdings. Its largest new stake was State Street Communication Services Select Sector SPDR ETF: 365,478 shares worth $17.9M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Sanofi, an estimated $40.1M trimmed.

  • Raymond James & Associates's largest Q3 2018 buy was State Street Communication Services Select Sector SPDR ETF: 365,478 shares worth $17.9M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q3 2018, an estimated $155M increase.
  • Raymond James & Associates's biggest Q3 2018 reduction was Sanofi, cutting an estimated $40.1M.
  • Raymond James & Associates fully exited Abaxis Inc in Q3 2018, selling an estimated $10.5M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $64.7B portfolio in Q3 2018.
  • Raymond James & Associates opened 235 new positions and closed 186 in Q3 2018.
  • Raymond James & Associates's portfolio value rose 8.8% quarter-over-quarter to $64.7B.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.